Pervasis Provides Update On Progress Of Clinical Program Targeting Peripheral Arterial Disease
Pervasis Therapeutics announced that the first cohort of patients has been fully enrolled in the Phase 1/2 clinical study of PVS-10200, an investigational new drug under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery. Initial study results from this patient cohort are expected …
Read more on Medical News Today
Popular Posts:
- Understanding Celiac Disease And Gluten Intolerance: A Video Program For Patients, Physicians, And Health Care Providers
- Congressman John Sullivan’s healthcare update
- Chronic Diseases and Health Care: New Trends in Diabetes, Arthritis, Osteoporosis, Fibromyalgia, Low Back Pain, Cardiovascular Disease, and Cancer
- Health Care Bill Update States Sue Over Health Care Bill Reform
- Health Care Bill Update States Sue Over Health Care Bill Reform
